CD8A and neoplasm: Upon combination treatment, we anticipate an increase of CD3+, CD8+ and FoxP3 + T cells in the TME, a dynamic change of the immune cell populations in the peripheral blood and an increased tumor regression as compared to historical controls due to the increased immune infiltrate within the tumor.